Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: A subgroup analysis of a large randomized clinical trial

Journal of Clinical Oncology

Volumn 27, Issue 25, 2009, Pages 4109-4115

  Sanoff, Hanna K ^a   Sargent, Daniel J ^a   Green, Erin M ^a   McLeod, Howard L ^a   Goldberg, Richard M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA; DRUG DERIVATIVE; FOLFOX PROTOCOL; IROX PROTOCOL; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AFRICAN AMERICAN; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DNA DETERMINATION; DOSE RESPONSE; DRUG METABOLISM; EUROPEAN AMERICAN; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUTROPENIA; PARESTHESIA; PHARMACOGENETICS; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; TREATMENT RESPONSE; VOMITING; BLOOD; CAUCASIAN; CLINICAL TRIAL; COLORECTAL TUMOR; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; ETHNOLOGY; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK; RISK ASSESSMENT; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; UNITED STATES;

ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUCOVORIN; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 70249096336     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.21.9527     Document Type: Article

References (28)

1. Shavers VL, Brown ML: Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst 94:334-357, 2002
2. Doubeni CA, Field TS, Buist DS, et al: Racial differences in tumor stage and survival for colorectal cancer in an insured population. Cancer 109:612-620, 2007
3. American Cancer Society: Colorectal Cancer Facts and Figures 2008-2010. Atlanta, GA, American Cancer Society, 2008
4. Irby K, Anderson WF, Henson DE, et al: Emerging and widening colorectal carcinoma disparities between blacks and whites in the United States (1975-2002). Cancer Epidemiol Biomarkers Prev 15: 792-797, 2006
5. Mayberry RM, Coates RJ, Hill HA, et al: Determinants of black/white differences in colon cancer survival. J Natl Cancer Inst 87:1686-1693, 1995
6. Schrag D, Cramer LD, Bach PB, et al: Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 93:850-857, 2001
7. Baldwin LM, Dobie SA, Billingsley K, et al: Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst 97:1211-1220, 2005
8. Cooper GS, Yuan Z, Landefeld CS, et al: Surgery for colorectal cancer: Race-related differences in rates and survival among Medicare beneficiaries. Am J Public Health 86:582-586, 1996
9. Chen VW, Fenoglio-Preiser CM, Wu XC, et al: Aggressiveness of colon carcinoma in blacks and whites: National Cancer Institute Black/White Cancer Survival Study Group. Cancer Epidemiol Biomarkers Prev 6:1087-1093, 1997
10. Cheng X, Chen VW, Steele B, et al: Subsite-specific incidence rate and stage of disease in colorectal cancer by race, gender, and age group in the United States, 1992-1997. Cancer 92:2547-2554, 2001
11. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502, 2006
12. Engen RM, Marsh S, Van Booven DJ, et al: Ethnic differences in pharmacogenetically relevant genes. Curr Drug Targets 7:1641-1648, 2006
13. Risch N, Burchard E, Ziv E, et al: Categorization of humans in biomedical research: Genes, race and disease. Genome Biol 3:comment2007, 2002
14. Burchard EG, Ziv E, Coyle N, et al: The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med 348: 1170-1175, 2003
15. Stephens JC, Schneider JA, Tanguay DA, et al: Haplotype variation and linkage disequilibrium in 313 human genes. Science 293:489-493, 2001
16. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
17. Marsh S, King CR, Garsa AA, et al: Pyrose-quencing of clinically relevant polymorphisms. Methods Mol Biol 311:97-114, 2005
18. Hoskins JM, Goldberg RM, Qu P, et al: UGT1A1*28 genotype and irinotecan-induced neutropenia: Dose matters. J Natl Cancer Inst 99:1290-1295, 2007
19. McCollum AD, Catalano PJ, Haller DG, et al: Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst 94:1160-1167, 2002
20. Dignam JJ, Colangelo L, Tian W, et al: Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: Findings from the National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst 91:1933-1940, 1999
21. Yothers G, Blackstock W, Wolmark N, et al: Outcomes in white patients and those of African (A) descent receiving adjuvant therapy for colon cancer. J Clin Oncol 25:167s, 2007 (suppl; abstr 4017)
22. Dominitz JA, Samsa GP, Landsman P, et al: Race, treatment, and survival among colorectal carcinoma patients in an equal-access medical system. Cancer 82:2312-2320, 1998
23. Delaunoit T, Alberts SR, Sargent DJ, et al: Chemotherapy permits resection of metastatic colorectal cancer: Experience from Intergroup N9741. Ann Oncol 16:425-429, 2005
24. Sanoff HK, Sargent DJ, Campbell ME, et al: Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 26:5721-5727, 2008
25. International HapMap Consortium: A haplo-type map of the human genome. Nature 437:1299-1320, 2005
26. Bamshad M, Wooding S, Salisbury BA, et al: Deconstructing the relationship between genetics and race. Nat Rev Genet 5:598-609, 2004
27. McLeod HL, Sargent DJ, Marsh S, et al: Pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5FU)/CPT-11, 5FU/ox-aliplatin (oxal), or CPT-11/oxal therapy for advanced colorectal cancer: Results from an intergroup trial. Proc Am Soc Clin Oncol 22:253a, 2003 (abstr 1013)
28. Van Cutsem E, Dirix L, Van Laethem JL, et al: Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: Results from a multinational, randomised phase II study. Br J Cancer 92:1055-1062, 2005